ATH-063

Phase 2Small molecule

AAthos Therapeutics Inc

ATH-063 is one of 44 small molecule programs targeting Ulcerative Colitis. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Ulcerative ColitisRecruiting

Ulcerative ColitisPhase 2

Recruiting

Competition

Competitive Landscape

91 competitors in Ulcerative Colitis

#DrugCompanyPhaseTrials

Stelara

Johnson & Johnson

Phase 3

10 2

Skyrizi

AbbVie

Phase 3

6 3

Jyseleca

Gilead

Phase 3

6 4

Humira

RRanbaxy Laboratories Limited

Phase 3

19 5

Velsipity

Pfizer

Phase 3

10 6

Mesalazine

Ferring

Phase 3

17 7

Plaquenil

Jazz Pharmaceuticals

Phase 2

1 8

Atorvastatin Calcium

Merck & Co.

Phase 2

1 9

Zasocitinib

Takeda

Phase 2

1 10

Lutikizumab

AbbVie

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2028

Phase 2Recruiting

Ulcerative Colitis

NCT07513181

Clinical

Trials by Indication[1]

Tics1 trial

Assessment of Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ATH-063 in Healthy Subjects

Completed·AAthos Therapeutics Inc·Phase 1·NCT05807971·76 enrolled

Ulcerative Colitis1 trial

A Phase 2b, Double-Blind, Placebo-Controlled, Multicenter Proof of Concept Clinical Study to Evaluate the Efficacy and Safety of ATH-063 Induction Therapy in Patients With Biologic Relapsed/Refractory Moderately to Severely Active Ulcerative Colitis (UC)

Recruiting·AAthos Therapeutics Inc·Phase 2·NCT07513181·120 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for ATH-063. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — ATH-063 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for ATH-063. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Athos Therapeutics Inc company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: AAthos Therapeutics Inc

ATH-063

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2028

Trials by Indication[1]

Tics1 trial

Ulcerative Colitis1 trial

References

Drug Info

Quick Facts

Related News